Behringwerke Aktiengesellschaft

Hoechst Aktiengesellschaft

Aventis Behring Gmbh

Peter Fuhge

Norbert Heimburger

Gerhardt Kumpe

Udo Becker

Konrad Braun

Eric P Paques

Wilfried Wormsbacher

Hans M Preis

Hansjorg Ronneberger

Hansj&ouml;rg Ronneberger

Wolfgang Burk

One-component tissue adhesive and a process for the production thereof

A description is given of a one-component tissue adhesive containing, in aqueous solution, fibrinogen, F XIII, a thrombin inhibitor, prothrombin factors, calcium ions and, where appropriate, a plasmin inhibitor and of a process for the production thereof. This adhesive can be reconstituted from a freeze-dried form with water. It can contain all active substances in pasteurized form and is then free of the risk of transmission of hepatitis and HTLV III.

A pasteurized human firbinogen which can be used therapeutically, and a process for its preparation are described.

Pasteurized human fibrinogen (HF), a process for its preparation, and

A solid fibrinogen formulation is described, which formulation contains, in addition to fibrinogen, a substance containing the urea or guanidine radical, and a process for its preparation. This formulation is used for the preparation of a fibrinogen solution which is suitable as an adhesive for human and animal tissue and as a fibrinogen concentrate for intravenous administration.

Readily dissolvable lyophilized fibrinogen formulation

A process for the production of an unnative and biologically active bonded collagen fiber sheet from human placentae is described, in which process collagen-containing material from placentae is treated with a neutral salt solution, a solution of citric acid and with pepsin. The degraded collagen material obtained in this manner is, where appropriate, treated with a crosslinking agent. The collagen material produced in this manner is used for producing bonded collagen fiber sheets which can be used, for example, as covering for wounds.

Process for the production of a bonded collagen fiber sheet

An agent for determining ristocetin cofactor (v.Willebrand factor) is described, which contains platelets which have been treated with a tanning agent, with a protease inhibitor and, optionally, with a dye-stuff, and ristocetin A.

Growing community of inventors

Lahntal, Germany

Peter Fuhge